MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To judge various intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key demo objectives had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, though among the exploratory ob... https://ldn19318954310.blog-ezine.com/30942582/bcat-in-4-an-overview